Santarus has signed exclusive license and supply agreements with Pharming Group NV granting Santarus the right to commercialize Rhucin (recombinant human C1 inhibitor) in North America for the treatment of acute attacks of hereditary angioedema (HAE) and other future indications. Santarus will pay Pharming a $15 million upfront fee, along with a $5 million milestone payment upon acceptance of the Rhucin’s BLA by the FDA. Additional payments are payable upon completing clinical and comme...